Long‐Term Oncological Outcome Comparison between Intermediate‐and High‐Dose Radioactive Iodine Ablation in Patients with Differentiated Thyroid Carcinoma: A …

K Kim, JS Bae, JS Kim - International Journal of Endocrinology, 2021 - Wiley Online Library
Background. Radioactive iodine (RAI) ablation is recommended for most patients with
differentiated thyroid carcinoma (DTC) after total thyroidectomy (TT). We aimed to compare …

Outcomes after radioiodine ablation in patients with thyroid cancer: Long‐term follow‐up of a Chinese randomized clinicaltrial

P Dong, Y Qu, L Yang, L Xiao, R Huang… - Clinical …, 2021 - Wiley Online Library
Objective Two large randomized trials of patients with differentiated thyroid cancer (DTC)
reported recently (HiLo and ESTIMABL1) found that the recurrence rate among patients who …

Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer

Y Iizuka, T Katagiri, K Ogura, T Mizowaki - Annals of Nuclear Medicine, 2019 - Springer
Objective This study aimed to compare the clinical outcomes of patients who received
radioactive iodine (RAI) ablation after undergoing thyroidectomy for intermediate-to-high-risk …

Radioiodine versus no radioiodine outcomes in low‐risk differentiated thyroid cancers: A propensity‐score matched analysis

S Satapathy, A Tupalli, KR Chandekar… - Clinical …, 2023 - Wiley Online Library
Abstract Objective The 2015 American Thyroid Association guidelines recommend against
radioiodine (RAI) ablation for patients with low‐risk papillary microcarcinoma. However, its …

Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients

C Schvartz, F Bonnetain, S Dabakuyo… - The Journal of …, 2012 - academic.oup.com
Context: American Thyroid Association and European Thyroid Association guidelines
cannot recommend for or against radioactive iodine (RAI) ablation after surgery in low-risk …

Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer

L Welsh, C Powell, B Pratt, K Harrington… - The Journal of …, 2013 - academic.oup.com
Context: Randomized trials show that low-dose (1.1 GBq [30 mCi]) radioiodide (RAI) has
efficacy equivalent to high-dose RAI (3.7 GBq [100 mCi]) in thyroid remnant ablation (TRA) …

Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients

MG Castagna, G Cevenini… - European journal of …, 2013 - academic.oup.com
Background In differentiated thyroid cancer (DTC) patients at intermediate risk of
recurrences, no evidences are provided regarding the optimal radioactive iodine (RAI) …

Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines

Y Sia, RV Dave, D Nour, JA Miller… - ANZ Journal of …, 2019 - Wiley Online Library
Abstract Background The 2009 American Thyroid Association (ATA) three‐tiered risk
stratification, and its updated version in 2015, provided clearer guidance on the use of …

[HTML][HTML] Re-treatment with adjuvant radioactive iodine does not improve recurrence-free survival of patients with differentiated thyroid cancer

C Bouvet, B Barres, F Kwiatkowski… - Frontiers in …, 2019 - frontiersin.org
Introduction: Loco regional persistence or recurrence of differentiated thyroid cancer (DTC)
is frequent despite initial thyroidectomy and radioactive iodine therapy (RAI). The aim of this …

Intermediate‐risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long‐term outcome study

S Ballal, R Soundararajan, A Garg… - Clinical …, 2016 - Wiley Online Library
Objective The mute question is whether patients with DTC of intermediate risk of recurrence,
second most common presentation, who were surgically ablated in the first place, ever …